Financials Pacira BioSciences, Inc.

Equities

PCRX

US6951271005

Pharmaceuticals

Market Closed - Nasdaq 04:00:07 2024-07-12 pm EDT 5-day change 1st Jan Change
21.74 USD -0.32% Intraday chart for Pacira BioSciences, Inc. +3.23% -35.57%

Valuation

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Capitalization 1 1,890 2,600 2,680 1,772 1,567 1,013 - -
Enterprise Value (EV) 1 2,118 2,962 3,144 2,357 1,811 1,209 1,049 1,013
P/E ratio -168 x 18 x 65.4 x 114 x 37.9 x 17.9 x 10.4 x 6.58 x
Yield - - - - - - - -
Capitalization / Revenue 4.49 x 6.05 x 4.95 x 2.66 x 2.32 x 1.46 x 1.32 x 1.2 x
EV / Revenue 5.03 x 6.89 x 5.81 x 3.53 x 2.68 x 1.74 x 1.37 x 1.2 x
EV / EBITDA 22.3 x 26.3 x 15.4 x 11.1 x 8.44 x 5.76 x 4 x 3.11 x
EV / FCF 30.5 x 40.6 x 39.4 x 20.5 x 13 x 6.91 x 5.1 x 3.87 x
FCF Yield 3.28% 2.47% 2.54% 4.89% 7.7% 14.5% 19.6% 25.9%
Price to Book 5.35 x 4.21 x 3.69 x 2.29 x - 1.08 x 0.92 x 0.78 x
Nbr of stocks (in thousands) 41,731 43,444 44,544 45,882 46,438 46,546 - -
Reference price 2 45.30 59.84 60.17 38.61 33.74 21.76 21.76 21.76
Announcement Date 2/20/20 2/25/21 2/24/22 2/28/23 2/29/24 - - -
1USD in Million2USD
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net sales 1 421 429.6 541.5 666.8 675 695.7 764.6 840.8
EBITDA 1 94.86 112.6 204 212.7 214.5 209.9 262.5 325.8
EBIT 1 75.28 99.3 189.2 194.8 197.7 189.8 241.9 292.2
Operating Margin 17.88% 23.11% 34.94% 29.21% 29.28% 27.29% 31.63% 34.75%
Earnings before Tax (EBT) 1 -10.75 20.09 56.4 13.3 61.7 81.36 109 -
Net income 1 -11.02 145.5 41.98 15.91 41.96 72.61 109.9 171
Net margin -2.62% 33.87% 7.75% 2.39% 6.22% 10.44% 14.37% 20.33%
EPS 2 -0.2700 3.330 0.9200 0.3400 0.8900 1.218 2.088 3.307
Free Cash Flow 1 69.5 73.03 79.85 115.2 139.5 175 205.8 262
FCF margin 16.51% 17% 14.75% 17.28% 20.67% 25.15% 26.92% 31.17%
FCF Conversion (EBITDA) 73.27% 64.87% 39.14% 54.15% 65.03% 83.39% 78.42% 80.42%
FCF Conversion (Net income) - 50.18% 190.21% 724.11% 332.47% 240.99% 187.37% 153.29%
Dividend per Share - - - - - - - -
Announcement Date 2/20/20 2/25/21 2/24/22 2/28/23 2/29/24 - - -
1USD in Million2USD
Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: December 2021 Q4 2022 Q1 2022 Q2 2022 Q3 2022 Q4 2023 Q1 2023 Q2 2023 Q3 2023 Q4 2024 Q1 2024 Q2 2024 Q3 2024 Q4 2025 Q1 2025 Q2
Net sales 1 159.2 158 169.4 167.5 172 160.3 169.5 163.9 181.2 167.1 173.7 171 183.9 182.2 190.9
EBITDA 1 69.34 53.83 44.92 55.23 58.77 41.9 54.26 52.94 65.39 44.58 52.1 51.08 61.83 56.64 63.16
EBIT 1 63.99 49.17 40.9 50.76 53.96 37.44 50.27 49.25 60.71 40.63 48.21 45.16 55.78 57.3 65
Operating Margin 40.2% 31.12% 24.14% 30.31% 31.38% 23.35% 29.66% 30.04% 33.5% 24.31% 27.76% 26.41% 30.33% 31.45% 34.04%
Earnings before Tax (EBT) 1 -6.197 7.294 22.01 2.069 -18.07 -26.47 37.85 16.6 33.72 13.64 20.42 22.26 25.05 20.81 27.24
Net income 1 -5.129 6.828 19.88 -0.693 -10.1 -19.54 25.76 10.86 24.87 8.979 15.2 14.41 19.92 14.98 19.61
Net margin -3.22% 4.32% 11.73% -0.41% -5.87% -12.18% 15.2% 6.62% 13.72% 5.37% 8.75% 8.43% 10.83% 8.22% 10.27%
EPS 2 -0.1200 0.1500 0.4000 -0.0200 -0.2200 -0.4300 0.5100 0.2300 0.5000 0.1900 0.3075 0.2850 0.4425 0.3100 0.4000
Dividend per Share - - - - - - - - - - - - - - -
Announcement Date 2/24/22 5/4/22 8/3/22 11/3/22 2/28/23 5/3/23 8/2/23 11/2/23 2/29/24 5/7/24 - - - - -
1USD in Million2USD
Estimates

Balance Sheet Analysis

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net Debt 1 228 363 464 585 244 196 35.9 -
Net Cash position 1 - - - - - - - -
Leverage (Debt/EBITDA) 2.402 x 3.222 x 2.273 x 2.751 x 1.137 x 0.9336 x 0.1368 x -
Free Cash Flow 1 69.5 73 79.9 115 139 175 206 262
ROE (net income / shareholders' equity) 20.9% 19.8% 20.2% 16% - 16.1% 16.9% 16.7%
ROA (Net income/ Total Assets) 9.3% 9.17% 8.16% 6.43% - 9.02% 10.1% 10.6%
Assets 1 -118.5 1,586 514.5 247.5 - 805 1,085 1,612
Book Value Per Share 2 8.470 14.20 16.30 16.90 - 20.20 23.70 27.80
Cash Flow per Share - - - - - - - -
Capex 1 10.2 37.8 45.9 30.1 15.2 18.4 18 19.6
Capex / Sales 2.41% 8.8% 8.47% 4.51% 2.25% 2.64% 2.35% 2.33%
Announcement Date 2/20/20 2/25/21 2/24/22 2/28/23 2/29/24 - - -
1USD in Million2USD
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Trading Rating
Investor Rating
ESG Refinitiv
B-
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
9
Last Close Price
21.76 USD
Average target price
41.78 USD
Spread / Average Target
+91.99%
Consensus
  1. Stock Market
  2. Equities
  3. PCRX Stock
  4. Financials Pacira BioSciences, Inc.